Massachusetts Votes on Legalizing Psychedelic Substances for Mental Health Therapy

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

Massachusetts voters are about to decide on a significant shift in mental health treatment options. Question 4, which is on the November 2024 ballot, would allow limited, regulated access to certain natural psychedelics like psilocybin for people 21 and older. The proposed law aims to open up new therapeutic options for those facing mental health struggles. If passed, Massachusetts would join other states that have already legalized psychedelics for specific therapeutic purposes. This initiative offers an alternative path for individuals who’ve tried traditional therapies without success. Let’s go over what this measure includes, why supporters are advocating for it and how it could change mental health care options.

What Question 4 Would Allow

Question 4, also known as the Legalization and Regulation of Psychedelic Substances Initiative, focuses on safe access to plant-based psychedelics under strict guidelines. It’s meant to address the mental health needs of individuals who might benefit from these treatments. Here’s what Question 4 is proposing to put in place:

  • Therapeutic Use Only: If approved, this measure would set up licensed centers where people 21 and older can access psychedelics under the supervision of a trained professional. These centers would be carefully regulated to make sure clients have a safe and supportive experience. The program would be managed by a new state commission dedicated to overseeing every aspect of the system, from licensing to health and safety requirements.
  • Limited Home Cultivation: The measure would allow adults to grow a small amount of psychedelic plants at home. They’d need to keep the area secure and no larger than a 12-by-12-foot space. This part of the law aims to let people have a limited, personal supply without needing to rely solely on licensed centers. It’s designed with safety in mind, including requirements that plants be kept out of reach of anyone under 21.
  • Controlled Sales and Local Tax Options: The proposal includes a 15% excise tax on licensed therapy centers that provide psychedelics. It also gives local governments the option to add up to a 2% tax. This revenue would support the program’s administration and fund additional mental health resources. Local areas could also set rules for where and when these centers operate, making it easier to adjust to each community’s needs.

Question 4 is designed to provide access to psychedelics in a way that’s controlled and focused on mental health benefits. Supporters believe it’s a responsible way to help people who might be out of options with traditional therapies.

How the System Would Work

The framework of Question 4 is based on a system of strict licensing and regulation, which aims to create a controlled and supportive environment for therapeutic use. To oversee this, a new commission called the Natural Psychedelic Substances Commission would be formed. This commission would set and enforce rules to make sure everything runs safely.

  • Regulating Access Through Licensing: The measure requires multiple license categories, each addressing a specific part of the process. For instance, there would be licenses for therapy centers, facilitators and even testing. This setup is meant to make sure that only qualified individuals and organizations handle and administer these substances. Each client would need to go through a preparation session before using psychedelics, followed by an integration session afterward to help process the experience.
  • Safety and Health Measures: Question 4 includes several protections aimed at keeping the experience as safe as possible. Before each session, facilitators would conduct health screenings and provide educational materials. This is meant to ensure that each client understands what to expect and that they’re in good health for the session. During each session, the facilitators would provide careful supervision to keep things secure and supportive. By setting high standards for health and safety, the initiative intends to make sure that everyone who uses psychedelics has a positive experience that supports their mental health journey.
  • Local Flexibility: Communities would have the freedom to decide when and where these licensed therapy centers can operate. While the law wouldn’t allow a complete ban, it does let local governments set restrictions based on their unique needs. This approach gives each area the option to control the time and place of these facilities, helping to address any local concerns while still providing access.

The proposed setup is designed to give people a supportive and controlled experience. It focuses on high standards and careful supervision to make sure that psychedelics are used responsibly.

Why Supporters Believe This Could Help Mental Health

Supporters of Question 4 see it as an opportunity to expand mental health treatment options for people who’ve struggled with other therapies. Groups like Massachusetts for Mental Health Options are behind the initiative, pointing out the positive results from research on psychedelics and mental health. For those dealing with conditions like PTSD, depression and end-of-life anxiety, psychedelics could offer a unique way to experience relief.

Researchers in Massachusetts have been exploring the effects of psychedelics for years, especially in combination with other treatments. Studies have shown that psychedelics can create positive changes in the brain when used in a controlled setting, often helping people gain new perspectives on their struggles. Institutions have been looking into the benefits of combining substances like psilocybin with therapies like MDMA for veterans and others who have had limited success with traditional treatments.

Supporters also feel that psychedelics can give hope to people who’ve reached the end of the road with standard treatments. Emily Oneschuk, the outreach director for Massachusetts for Mental Health Options and a U.S. Navy veteran, believes psychedelics could make a real difference for veterans struggling after their service.

Why Some People Have Concerns

Not everyone is on board with the idea. Some groups worry that this new access to psychedelics could bring risks along with it. The Coalition for Safe Communities, which opposes Question 4, has raised questions about safety, the speed of the rollout and the potential for misuse. Chris Keohan, a spokesperson for the group, has said that while the therapeutic benefits are recognized, the proposal might be moving “way too far, way too quickly.”

One concern raised by opponents is around home cultivation. While the law limits the size of personal grow areas, some worry that allowing people to grow these plants at home could lead to unauthorized or unregulated use. There’s also concern that psychedelics remain illegal under federal law, which could create conflicts or complications with the state law. Opponents feel that these factors could make it harder to enforce safe use.

There are also concerns about how the new commission will handle oversight. The proposal would create a system similar to the one used for cannabis, but opponents point to challenges that have come up with the state’s Cannabis Control Commission. Staffing issues, regulatory delays and high-level suspensions have led some to worry about similar problems with the new commission for psychedelics. Some mental health professionals believe there’s still more to learn before making a big change like this one.

What Could Happen if Question 4 Passes

If voters approve Question 4, Massachusetts would be one of the first places to allow regulated access to psychedelics specifically for mental health treatment. For thousands of residents dealing with serious mental health challenges, this measure could open doors to treatments that offer relief in a safe and supportive environment. The initiative also sets up a controlled system that focuses on therapeutic benefits while keeping health and safety in mind.

Passing this measure could change the outlook of mental health care, providing options to those who feel like they’ve tried everything else. Research shows that psychedelics can create meaningful breakthroughs in people’s lives when used in a structured, supportive environment. By passing Question 4, Massachusetts would be stepping forward to provide these alternatives in a careful and thoughtful way.

As Election Day approaches, voters will have an important decision to make. For those supporting a “yes” vote on Question 4, it’s a chance to improve mental health care and give people new tools for healing. This measure could be a valuable addition to mental health resources, offering people a safe way to try something that might finally make a difference in their lives.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.